Mouse FLT3/Flk-2 Protein
Catalog No: FLT3-MF001
- Species
- Mouse
- Expression System
- HEK293
- Tag
- an hFc (IgG1)
Product overview
Recombinant Mouse FLT3/Flk-2 Protein is expressed in HEK293 cells with an hFc (IgG1) tag at the C-terminus. It contains amino acid residues Asn28-Ser544 (UniProt accession: Q00342).
Product Details
- Molecular Aliases
- CD135; FLK2; STK-1; FLT-3;STK1; FLT3
- Protein Length
- Asn28-Ser544
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 84.78 kDa. Due to glycosylation, the protein migrates to 100-120 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 85% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Mouse FLT3 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Mouse FLT3 is greater than 85% as determined by SEC-HPLC.
Background
The Flt-3 (fms-like tyrosine kinase) receptor, also named Flk-2 (fetal liver kinase) and Stk-1(stem cell tyrosine kinase) is a member of the class III subfamily of receptor tyrosine kinases that also includes KIT, the receptor for SCF and FMS, the receptor for M-CSF. Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1.
References
- Small D. Targeting FLT3 for the Treatment of Leukemia[J]. Seminars in Hematology, 2008, 45(supp-S2).
Have questions about this product?
Our technical team can help with product selection, application questions and order support.